Simulations indicated that HCQ and ATM would have a synergistic effect in the treatment of the infection, where HCQ acts as a competitive binder against gangliosides, another proposed receptor for S protein, and ATM interacts with the tip of SARS‐CoV‐2‐spike.[60] Although these results seemed promising, the outcomes of clinical trials appeared highly controversial and the hypothesis of adopting the combined HCQ and ATM therapy has been abandoned. This evidence concerns the gene PROS1 and infection.